[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"colorectal-cancer-liver-metastases-crlm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:colorectal-cancer-liver-metastases-crlm":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,53,77,103,129,151],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":4},"100636840","phase-2-hepatic-arterial-infusion-of-liposomal-irinotecan-plus-oxaliplatin-and-capecitabine-as-adjuvant-therapy-for-colorectal-cancer-liver-metastases-100636840",false,"NCT07570914","Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases","An Exploratory Clinical Study of Hepatic Arterial Infusion of Liposomal Irinotecan Combined With Oxaliplatin and Capecitabine as Postoperative Adjuvant Therapy for Colorectal Cancer Liver Metastases","Inclusion Criteria:\n\n1. Age 18 to 75 years.\n2. Completion of radical resection of the colorectal primary tumor and liver metastases within 12 weeks before enrollment, with postoperative imaging showing no residual lesion, recurrence, or extrahepatic metastasis, indicating no evidence of disease.\n3. Histologically confirmed colorectal cancer liver metastases.\n4. ECOG performance status of 0 or 1.\n5. Expected survival of at least 3 months.\n6. Clinical risk score of 3 or higher.\n7. Adequate bone marrow function, defined as absolute neutrophil count \\>2 × 10\\^9\u002FL, hemoglobin \\>9.0 g\u002FdL, and platelet count \\>100 × 10\\^9\u002FL.\n8. Adequate renal function, defined as serum creatinine ≤1.5 × the upper limit of normal or creatinine clearance ≥30 mL\u002Fmin according to the Cockcroft-Gault formula.\n9. Adequate hepatic function, defined as serum bilirubin ≤1.5 × the upper limit of normal, transaminases ≤2.5 × the upper limit of normal or ≤5 × the upper limit of normal if liver metastasis is present, and alkaline phosphatase ≤5 × the upper limit of normal.\n10. Female participants must not be pregnant or breastfeeding. Women of childbearing potential and male participants must use effective contraception during the study and for 6 months after completion of study treatment.\n11. Good compliance, ability to understand the study procedures, and willingness to sign written informed consent.\n\nExclusion Criteria:\n\n1. Contraindication to capecitabine, oxaliplatin, or irinotecan.\n2. Any history of hepatic interventional therapy, including transarterial infusion, hepatic arterial infusion, or transarterial chemoembolization.\n3. Receipt of adjuvant chemotherapy containing irinotecan after resection of the primary tumor, or receipt of adjuvant therapy without irinotecan with the last dose administered within 3 months before enrollment.\n4. Dihydropyrimidine dehydrogenase deficiency.\n5. History of severe cardiovascular disease resulting in inability to tolerate treatment.\n6. Peripheral neuropathy greater than Grade 1.\n7. History of another malignancy within the previous 5 years, except cured carcinoma in situ or basal cell carcinoma of the skin.\n8. History of allogeneic organ transplantation.\n9. Requirement for renal dialysis.\n10. Breastfeeding, pregnancy, or inadequate contraception in women of childbearing potential.\n11. Uncontrolled concomitant disease, including but not limited to severe active or uncontrolled infection, symptomatic congestive heart failure, unstable angina, arrhythmia, uncontrolled diabetes, or psychiatric illness that may affect study compliance.\n12. Participation in another clinical trial currently or within 4 weeks before enrollment.\n13. Any condition that, in the investigator's judgment, makes the participant unsuitable for the study.","ALL","18 Years","75 Years",{"count":20,"type":21},28,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a prospective, single-center, single-arm exploratory clinical study designed to evaluate the efficacy and safety of hepatic arterial infusion of liposomal irinotecan combined with systemic oxaliplatin and capecitabine as postoperative adjuvant therapy in patients with colorectal cancer liver metastases after radical resection.\n\nEligible participants must have histologically confirmed colorectal cancer liver metastases and have completed radical resection of the colorectal primary tumor and liver metastases within 12 weeks before enrollment. Postoperative imaging must show no residual lesion, recurrence, or extrahepatic metastasis, indicating no evidence of disease. Participants will receive hepatic arterial infusion chemotherapy with liposomal irinotecan plus systemic chemotherapy with oxaliplatin and capecitabine every 21 days for 2 to 4 cycles. After 2 cycles, treatment continuation will be determined by the investigator based on efficacy and tolerability.",[27,28,29],"Colorectal Cancer Liver Metastases (CRLM)","Colorectal Cancer","Liver Metastasis",[31,32,33,34,35,36,37,38,39,40],"Colorectal cancer","Colorectal cancer liver metastases","Postoperative adjuvant therapy","Hepatic arterial infusion chemotherapy","Liposomal irinotecan","Oxaliplatin","Capecitabine","Disease-free survival","Hepatic recurrence-free survival","No evidence of disease","NOT_YET_RECRUITING","2026-04-29",{"date":44,"type":45},"2026-05-06","ACTUAL",{"date":47,"type":21},"2026-05-30",{"date":49,"type":21},"2032-05-30",{"name":51,"class":52},"Tianjin Medical University Cancer Institute and Hospital","OTHER",{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100634830","phase-2-ak104-plus-radiotherapy-combined-with-standard-therapy-versus-standard-therapy-as-first-line-treatment-for-pmmrmss-crlm-apsoc-100634830","NCT07544784","AK104 Plus Radiotherapy Combined With Standard Therapy Versus Standard Therapy as First-Line Treatment for pMMR\u002FMSS CRLM (APSOC)","Efficacy of Cadonilimab (AK104) Plus Radiotherapy Combined With Standard Therapy Versus Standard Therapy as First-Line Treatment for pMMR\u002FMSS Colorectal Cancer With Liver Metastases: A Prospective, Randomized Controlled, Single-Center Phase II Clinical Trial (APSOC)","APSOC","Inclusion Criteria:\n\n1. Age ≥ 18 years, with no gender restriction;\n2. Histologically or cytologically confirmed colorectal cancer;\n3. Presence of liver metastases, with at least one measurable target lesion (per RECIST 1.1 criteria) in addition to a single liver metastatic lesion amenable to radiotherapy; patients with initially resectable colorectal cancer liver metastases are excluded;\n4. Treatment-naive patients; or patients with postoperative recurrence who have not received any anti-tumor therapy within 6 months and at least 6 months have elapsed since the last adjuvant chemotherapy;\n5. ECOG performance status score of 0-1;\n6. Expected overall survival ≥ 3 months;\n7. Adequate organ function and reserve, meeting the following laboratory criteria within 7 days prior to screening (inclusive):\n\n   HB ≥ 90 g\u002FdL, ANC ≥ 1.5 × 10⁹\u002FL, PLT ≥ 100 × 10⁹\u002FL; BIL \\\u003C 1.5 × ULN, ALT and AST \\\u003C 2.5 × ULN; ALT and AST \\\u003C 5 × ULN in the presence of liver metastases; Serum Cr ≤ 1 × ULN, creatinine clearance \\> 50 mL\u002Fmin (calculated using the Cockcroft-Gault formula); International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 × ULN; for patients on anticoagulant therapy, PT within the intended therapeutic range is acceptable;\n8. Voluntary participation in the study, provision of signed informed consent, good compliance, and willingness to comply with follow-up procedures.\n\nExclusion Criteria:\n\n1. History of other malignancy within 3 years prior to enrollment, except for cured carcinoma in situ of the cervix or basal cell carcinoma of the skin.\n2. Symptomatic brain or meningeal metastases, except those treated locally and stable for more than 2 months without symptoms.\n3. Presence of gastrointestinal obstruction, gastrointestinal bleeding (≥+++ fecal occult blood), or perforation.\n4. Prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, CD137, or CTLA-4 antibodies, or any other antibodies or drugs specifically targeting T-cell co-stimulatory or checkpoint pathways.\n5. Subjects with active autoimmune disease or a history of autoimmune disease that may relapse (e.g., systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, autoimmune thyroid disease, multiple sclerosis, vasculitis, glomerulonephritis, etc.), or patients at high risk (e.g., organ transplant recipients requiring immunosuppressive therapy).\n\n   However, patients with vitiligo, psoriasis, alopecia, or Graves' disease not requiring systemic therapy in the past 2 years, hypothyroidism requiring only thyroid hormone replacement, or type 1 diabetes mellitus requiring only insulin replacement may be enrolled.\n6. Current interstitial lung disease or pneumonitis, pulmonary fibrosis, acute pulmonary disease, or radiation pneumonitis.\n7. Participation in another investigational drug study within 4 weeks prior to the first dose (based on receipt of investigational product), unless participation was in an observational (non-interventional) study.\n8. Use of immunosuppressive medications within 4 weeks prior to the first study treatment, excluding topical, nasal, inhaled, or other local corticosteroids; physiological doses of systemic corticosteroids (i.e., ≤10 mg\u002Fday prednisone or equivalent); or short-term (≤7 days) corticosteroids for prophylaxis or treatment of non-autoimmune allergic conditions.\n9. Administration of a live attenuated vaccine within 4 weeks prior to the first dose or planned administration during the study period.\n\n   Note: Administration of inactivated seasonal influenza vaccine by injection within 4 weeks prior to the first dose is permitted; live attenuated influenza vaccines are not permitted.\n10. Major surgical procedure (craniotomy, thoracotomy, or laparotomy) within 4 weeks prior to the first study treatment, or expectation of requiring major non-study surgery during the study period.\n11. History of human immunodeficiency virus (HIV) infection (i.e., positive HIV antibody), other acquired or congenital immunodeficiency disorders, organ transplantation, or stem cell transplantation.\n12. Active chronic hepatitis B or active hepatitis C. Hepatitis B carriers, patients with hepatitis B stabilized by antiviral therapy (HBV DNA ≤ 200 IU\u002FmL or copy number \\\u003C 1000 copies\u002FmL), and patients with cured hepatitis C (negative HCV RNA) may be enrolled.\n13. Known active tuberculosis.\n14. Severe infection within 4 weeks prior to the first dose, or active infection requiring oral or intravenous antibiotic therapy within 2 weeks prior to the first dose.\n15. Symptomatic congestive heart failure (NYHA Class II-IV) or symptomatic or poorly controlled cardiac arrhythmia.\n16. Uncontrolled arterial hypertension despite standard treatment (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg).\n17. Any arterial thromboembolic event within 6 months prior to enrollment, including myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack.\n18. History of deep vein thrombosis, pulmonary embolism, or other severe thromboembolism within 3 months prior to enrollment.\n\n    Catheter-related thrombosis or superficial venous thrombosis associated with an implanted venous port or catheter is not considered severe thromboembolism.\n19. Documented history of neurological or psychiatric disorders: e.g., epilepsy, dementia, poor compliance, or presence of peripheral neurological disorders.\n20. Alcohol dependence or history of drug abuse within the past 1 year.\n21. Pregnant or lactating women; individuals of childbearing potential without adequate contraception.\n22. Other acute or chronic medical conditions, psychiatric disorders, or abnormal laboratory values that may: increase the risk associated with study participation or study drug administration; interfere with the interpretation of study results; and in the opinion of the investigator, render the patient ineligible for study participation.",{"count":62,"type":21},73,[24],"This is a prospective, randomized controlled, single-center phase II clinical study. It aims to compare the efficacy of AK104 plus radiotherapy combined with standard therapy versus standard therapy as first-line treatment for liver metastases from metastatic colorectal cancer.",[27],"RECRUITING","2026-04-15",{"date":69,"type":45},"2026-04-22",{"date":71,"type":45},"2025-11-04",{"date":73,"type":21},"2028-11-01",{"name":75,"class":52},"Fudan University",1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":84,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":89,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":76},"100623638","ai-based-prediction-of-liver-metastasis-in-colorectal-cancer-a-retrospective-study-100623638","NCT07399236","AI-Based Prediction of Liver Metastasis in Colorectal Cancer (A Retrospective Study)","A Multicenter, Retrospective, Observational Study to Develop and Validate a Multimodal Deep Learning Model for Predicting Metachronous Liver Metastasis in Colorectal Cancer Patients After Curative Resection","Inclusion Criteria:\n\n* Age 18-75 years, any gender.\n* Histologically confirmed primary colon or rectal adenocarcinoma.\n* Underwent curative radical resection (R0 resection) for colorectal cancer.\n* Preoperative contrast-enhanced abdominal\u002Fpelvic CT scan performed within 1 month before surgery, with acceptable image quality.\n* No evidence of distant metastasis (including synchronous liver metastasis) on preoperative or intraoperative exploration.\n\nExclusion Criteria:\n\n* History of other malignant tumors.\n* Previous history of liver surgery or liver transplantation.\n* Missing clinical, imaging, or pathological data required for the study.\n* Death within the perioperative period (within 30 days after surgery).\n* Lack of regular follow-up information.",{"count":85,"type":21},1500,"OBSERVATIONAL","This multicenter, retrospective study aims to develop and validate a multimodal deep learning model for predicting the risk of metachronous liver metastasis in patients with stage I-III colorectal cancer following curative resection. The model will integrate preoperative contrast-enhanced CT imaging, digitized histopathological whole-slide images, and standard clinical-pathological data.\n\nThe primary objective is to assess the model's discriminatory performance, measured by the area under the receiver operating characteristic curve (AUC), and to compare its predictive accuracy against traditional prognostic factors such as TNM staging and serum carcinoembryonic antigen levels. This research utilizes existing archival data; no direct patient contact or intervention is involved. The ultimate goal is to provide a robust, data-driven tool for improved risk stratification, which could potentially guide personalized surveillance strategies and adjuvant therapy decisions in the future.",[27],[90,91,92,93],"Colorectal cancer liver metastases (CRLM)","deep learning","multimodal","predictive model","2026-02-09",{"date":96,"type":45},"2026-02-10",{"date":98,"type":45},"2015-01-01",{"date":100,"type":21},"2026-01-30",{"name":102,"class":52},"Tongji Hospital",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":76},"100610218","exosome-derived-extrahepatic-metastasis-detection-by-liquid-biopsy-in-colorectal-cancer-liver-metastases-100610218","NCT07224724","Exosome-derived Extrahepatic Metastasis Detection By Liquid Biopsy In Colorectal Cancer Liver Metastases","EXELION","Inclusion Criteria:\n\n* Adults (≥18 years old)\n* Histologically- or cytologically-confirmed colorectal cancer that is metastatic\n* Availability of pre-treatment plasma samples\n* Written informed consent provided\n* Sufficient clinical and imaging data to determine presence\u002Fabsence of extrahepatic metastasis\n\nExclusion Criteria:\n\n* Prior malignancies within 5 years\n* Poor sample quality or hemolysis\n* Inability to provide informed consent",{"count":111,"type":21},500,"Colorectal cancer is the third most common malignancy worldwide, and prognosis largely depends on how effectively metastatic disease is managed. The liver is the most frequent and prognostically important site of metastasis, and patients responding well to chemotherapy may become candidates for curative hepatic resection. However, the presence of extrahepatic metastasis (EHM) critically influences treatment eligibility and survival. Although clinical scores such as the Fong and Beppu systems include EHM as a determinant, its detection by imaging remains limited, especially for small or occult lesions. Accurate identification of EHM is also essential when considering liver transplantation for unresectable colorectal liver metastases (CRLM), where EHM remains an exclusion criterion.\n\nThe EXELION Study aims to develop a non-invasive diagnostic model using serum exosomal microRNAs (miRNAs) to detect both hepatic and extrahepatic metastases in patients with CRLM. By integrating circulating miRNA profiling with machine learning-based analysis, this study seeks to supplement imaging diagnostics, improve treatment stratification, and enhance clinical decision-making for metastatic colorectal cancer.",[27,114],"Metastatic Colorectal Carcinoma (mCRC)",[116,117,118,119],"CRC","Extrahepatic metastasis","liquid biopsy","Early detection","2026-01-27",{"date":122,"type":45},"2026-01-28",{"date":124,"type":45},"2024-06-01",{"date":126,"type":21},"2026-06-18",{"name":128,"class":52},"City of Hope Medical Center",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":136,"enrollmentInfo":137,"targetDuration":139,"studyType":86,"phases":4,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":4},"100583712","mrd-guided-surveillance-in-resectable-stage-iv-metastatic-colorectal-cancer-surveillance-ii-100583712","NCT06879886","MRD-Guided Surveillance in Resectable Stage IV Metastatic Colorectal Cancer (SURVEILLANCE-II)","SURII","Inclusion Criteria:\n\n1. Age 18-80 years old, male or female;\n2. histologically confirmed primary foci of colorectal adenocarcinoma (i.e., adenoepithelial carcinoma, including adenocarcinoma, mucinous adenocarcinoma, imprinted cell carcinoma, and undifferentiated carcinoma; excluding adenosquamous carcinoma); (3) Preoperative stage IV and no surgical resection; (4) Not receiving chemotherapy, radiotherapy, targeted therapy or other anti-tumor therapy;\n\n5\\) Surgical resection of primary\u002Fmetastatic foci is possible; 6) ECOG score 0-1; 7) Subjects voluntarily enrolled in the study and signed the informed consent, good compliance, and actively cooperate with the regular clinical follow-up clinic back in the hospital.\n\nExclusion Criteria:\n\n1. Previous other malignant tumors (including non-adenocarcinoma colorectal cancer);\n2. Pregnant and lactating women;\n3. Patients with other concurrent illnesses that, in the judgment of the investigator, may interfere with follow-up and short-term survival;\n4. The subject has other factors that may cause this study to be forced to be terminated halfway, such as other serious illnesses (including psychiatric illnesses) that require comorbid treatment, serious laboratory test abnormalities, accompanied by family or social factors that would affect the safety of the subject, or the collection of data and samples.","80 Years",{"count":138,"type":21},181,"2 Years","This study aims to explore the relationship between minimal residual disease (MRD) status and disease recurrence in patients with resectable stage IV metastatic colorectal cancer (mCRC). MRD refers to the presence of cancer cells that remain in the body after treatment but are undetectable by traditional imaging methods. The study will use a blood-based circulating tumor DNA (ctDNA) methylation test to assess its ability to predict cancer recurrence and survival outcomes.\n\nPatients who are newly diagnosed with resectable stage IV mCRC and have not yet received any treatment will be enrolled. Blood samples will be collected at multiple time points, including before surgery, after surgery, and during follow-up visits over two years. The study will compare MRD status with recurrence-free survival (RFS), overall survival (OS), and the time it takes for MRD to detect recurrence compared to standard imaging methods.\n\nThe goal is to determine whether MRD monitoring can provide an early warning of cancer recurrence and help guide treatment decisions. This study may offer valuable insights into improving postoperative surveillance and personalized treatment strategies for metastatic colorectal cancer patients.",[142,27],"Colorectal Cancer (CRC)","2025-03-11",{"date":145,"type":45},"2025-03-17",{"date":147,"type":21},"2025-08-01",{"date":149,"type":21},"2028-07-31",{"name":75,"class":52},{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":175},"100472196","the-dragon-2-trial-100472196","NCT05428735","The DRAGON 2 Trial","An International Multicenter Randomized Controlled Trial to Compare Combined Portal and Hepatic Vein Embolization (PVE\u002FHVE) with PVE Alone in Patients with Colorectal Liver Cancer Metastases (CRLM) and a Small Future Liver Remnant (FLR)","DRAGON 2","Inclusion Criteria:\n\n* Patients with primarily unresectable\u002F potentially resectable CRLM with a FLR \\\u003C30% (\\\u003C40% in chemotherapy damaged livers)\n* Patients with non-resected primary CRC may be included if there is an intention to resect the CRC after the liver treatment (liver first approach) or simultaneously during one of the liver procedures.\n* Patients with resectable or ablatable lung or brain metastases can be included (statement about the resectability of these extrahepatic metastases by a tumor board needs to be available)\n* 18 Years and older\n* Men and women\n* Able to understand the trial and provide informed consent.\n\nExclusion Criteria:\n\n* Pregnant or lactating female.\n* Premenopausal females not able or willing to commit to oral contraception\n* Patients with prohibitive comorbidities, decision made by local team\n* Any patient with non-resectable or non-ablatable extrahepatic disease\n* Patients with hepatic malignancies other than CRLM\n* Progression of disease by RECIST criteria after cytoreduction chemotherapy\n* Complete response after conversion chemotherapy\n* Staging CT and (if indicated) CT\u002FMRI brain that demonstrates non-resectable extrahepatic disease\n* The anatomy of the liver or manifestation of tumors in relation to the liver veins prohibits the use of combined PVE\u002FHVE.",{"count":160,"type":21},348,[162],"NA","In the randomized controlled DRAGON 2 trial study subjects will be randomized between two arms, PVE alone (control group) and PVE\u002FHVE (interventional group).",[27,165],"Small Future Liver Remnant (FLR)","2024-10-29",{"date":168,"type":45},"2024-11-01",{"date":170,"type":45},"2022-04-01",{"date":172,"type":21},"2029-06-30",{"name":174,"class":52},"Maastricht University",24]